Prior Authorization Likely for QL / LA / SP Products

Prior authorization is commonly required for products flagged with QL (Quantity Limit), LA (Limited Availability), or SP (Specialty). When a drug in the formulary shows any of these Requirements/Limits codes, providers should assume prior authorization may be needed and contact Member Services or the plan’s provider portal to confirm and submit a PA request before dispensing.

• Affected flags: QL, LA, SP
• Examples: TOBI PODHALER (LA, SP); APRETUDE (LA, SP); many injectable biologic/antineoplastic agents marked SP or LA

Prior Authorization for SP‑Labeled Products

Products explicitly labeled SP (Specialty) frequently require prior authorization due to special handling, monitoring, or distribution requirements. Injectable biologics and antineoplastic agents often carry SP and will generally be routed through specialty pharmacy or prior authorization workflows.

• Common SP examples: rituximab (RUXIENCE) - Requirements/Limits = SP
• Antineoplastics and many infusions show SP designation

Specialty / Limited‑Access Annotations

LA (Limited Availability) and SP (Specialty) annotations indicate products that may be routed through specialty channels or have limited pharmacy distribution. These flags can change where and how a prescription is filled and may require specialty pharmacy enrollment or shipment coordination.

• LA = may be available only at select pharmacies
• SP = specialty handling, may need patient education/monitoring
• Examples: OFEV (LA, SP); JYNARQUE (LA, SP)

PA May Be Required for LA / SP / QL Products

If a medication is marked LA, SP, or has a QL, providers should verify PA requirements before prescribing. Failure to obtain prior authorization when required may result in claim denial or member out‑of‑pocket responsibility.

• Contact Member Services: 877-793-6253 (TTY: 711)
• Check formulary Requirements/Limits code on the drug line
• Obtain PA prior to dispensing when required

Specialty / Limited‑Access Products May Require Prior Authorization

Specialty or limited‑access products (SP/LA) may require additional clinical documentation, prior authorization, or routing through a specialty pharmacy. Providers should prepare to submit indication, prior treatment history, and relevant labs or monitoring plans.

• Examples: biologics (ENTYVIO, OMVOH), antineoplastics, and certain orphan drugs
• Prepare diagnosis, prior therapy, and monitoring plan with PA submission

Tier 2 Inhaler Prior Authorization Likelihood

Tier 2 inhalers and combination inhaled corticosteroid products often carry quantity limits and may require prior authorization for overrides. Verify QL values on the formulary (for example, 1 or 2 inhalers per 30 days) and include justification if requesting additional units.

• Examples: ADVAIR HFA = QL (1 inhaler/30 days)
• Albuterol inhalers = QL (2 inhalers/30 days)
• TRELEGY/ANORO/ARNUITY have specific blister/quantity QLs

Specialty / Limited‑Access Agents Require Authorization

Many specialty and limited‑access agents require authorization and may be subject to managed distribution, specialty pharmacy fill, or program-specific enrollment. Confirm payer routing and required forms ahead of treatment initiation.

• Biologic examples: ENTYVIO (LA, SP), INFLECTRA (SP)
• Oncology biologics and infused therapies commonly require PA and specialty routing

Prior Authorization and Specialty Flags Impact Coverage

Requirements/Limits flags (SP, LA, QL, ST, OTC) influence coverage decisions. When a drug line shows these flags, submit supporting clinical documentation and follow the plan’s PA checklist to avoid denials.

• ST (Step Therapy) may require trials of preferred agents before approval
• OTC or blank Requirements/Limits may affect benefit coverage
• Use the drug’s Tier and Requirements/Limits code when preparing documentation

Specialty / Limited Access Requirement

Specialty and limited access flags typically mean additional administrative steps are required. Plans may require specialty pharmacy enrollment, specific dispensing sites, or case management prior to approval.

• Examples: MAYZENT (LA, SP), MAVENCLAD (LA, SP)
• Coordinate with specialty pharmacy to ensure timely start of therapy

Specialty / Injectable Products Handling

Injectable, intra‑articular, and infused specialty products often need special handling and prior authorization. Ensure infusion centers, administration codes, and drug‑specific documentation are included with PA requests.

• Intra‑articular products: SYNVISC, VISCO‑3 (Requirements/Limits noted)
• Infused biologics/chemotherapy: many listed under ANTINEOPLASTIC AGENTS carry SP

Prior Authorization and Coverage Handling

When Requirements/Limits indicate prior authorization, provide clear clinical rationale, prior medication history, and any required lab or specialist documentation. Use the formulary Tier and Requirements/Limits codes to guide the PA submission.

• Include Tier and Requirements/Limits line from formulary in the PA
• Attach prior therapy notes, labs, and relevant specialty consults
• Document quantity requested relative to QL limits

Special Access Flags May Trigger Additional Review

Special access flags such as LA or program‑specific annotations (e.g., SP, special program) may trigger additional review steps or enrollment in manufacturer or plan programs. Check the formulary entry for these flags and follow the plan’s special program instructions.

• TOBI PODHALER listed LA, SP — may need special access handling
• BEYFORTUS listed SP — may be routed through a specialty program

Special Program Flag May Require Authorization

Some drugs carry a Special Program (SP) flag that requires program enrollment or additional administrative steps prior to coverage. Confirm program requirements and include required forms with the PA to avoid processing delays.

• SP examples: BEYFORTUS, many antineoplastics and specialty immunologics
• Confirm whether manufacturer or plan program enrollment is needed

Requirements / Limits Flags May Trigger Denials

Requirements/Limits flags can be grounds for denial if unmet. If a request exceeds quantity limits, lacks step‑therapy fulfillment, or omits required documentation, the claim is at higher risk for denial.

• Potential denial triggers: exceeding QL, not meeting ST, missing PA
• Example QLs: pregabalin strength‑specific QLs; anticoagulants with monthly QLs

Potential Denial Trigger: Unmet Formulary Requirements / Limits

Unmet formulary requirements — such as exceeding QLs, failing to follow ST, or not providing required documentation for LA/SP products — are common reasons for PA denial. Verify the formulary line and provide all requested clinical information.

• Check QL numeric thresholds on formulary entries
• Provide treatment history to satisfy ST when applicable

Quantity Limit Exceedance — Action Required

Quantity limits are enforced on many drug lines. Requests that exceed the stated QL should include clinical justification, prior authorization, and dosage rationale to support approval.

• Common QL examples: abacavir soln QL (960 mls/30 days); lamivudine soln QL (960 mls/30 days)
• Anticoagulants and inhalers frequently have QLs listed

Prior Authorization and Specialty Limits Present

Specialty drugs frequently carry both prior authorization requirements and specialty limits. Expect additional documentation and case management steps for products such as monoclonal antibodies, infused agents, and certain orphan therapies.

• Examples: ENTYVIO (LA, SP), OMVOH (LA, SP), MAVENCLAD (LA, SP)
• Coordinate PA with specialty pharmacy to include administration schedule and monitoring plan

Formulary / Requirements Implications for Documentation

Formulary annotations (Tier, Requirements/Limits) determine coverage and documentation needs. When preparing a PA, cite the formulary line (drug name, strength, Tier, Requirements/Limits) and supply supporting clinical records.

• Use the formulary Tier to justify medical necessity (e.g., Tier 2 vs Tier 1)
• Include the exact Requirements/Limits text from the formulary in submissions

Quantity Limits Trigger Coverage Review

Quantity limits on the formulary often trigger coverage review. When requesting amounts above the QL, include dosing schedule, therapeutic rationale, and any weight‑ or regimen‑based calculations in the PA.

• Inhaler QLs (e.g., 1 inhaler/30 days) require justification for additional fills
• Anticoagulant and antiepileptic QLs listed should be referenced in request

Brand vs. Generic Documentation

When there is a brand vs. generic consideration, document the clinical rationale for brand‑necessary requests (allergy, intolerance, therapeutic failure of generics) and include previous medication trials in the PA.

• If prescribing a brand product when generics exist, include prior trial and failure of generic alternatives
• Document adverse reactions or clinical reasons for brand medical necessity

Adhere to Quantity Limits

Adhere to stated quantity limits; do not dispense amounts exceeding formulary QLs without an approved PA. Pharmacy and provider dispensing should reflect the QL units (tablets, inhalers, blisters, mLs) listed on the formulary.

• Follow unit definition on formulary (e.g., inhaler, blister, tablets, mLs)
• Request PA when more than QL is clinically necessary

Quantity Limit Documentation

Document quantity rationale in the PA: include dosing frequency, duration, and calculation leading to the total quantity requested. Attach prescribing notes and any relevant weight or body‑surface area calculations for specialty dosing.

• For liquids: convert mL limits to dosing schedule in notes
• For weight‑based dosing, attach calculation and patient weight/date

Quantity Limits Documented on Formulary — Use in Submissions

Formulary entries list QLs and other Requirements/Limits; reference these exact notations in PA requests. Use the formulary line item to show the plan’s published limit and explain why an exception is necessary.

• Cite formulary line (drug, strength, Requirements/Limits text) in the PA cover letter
• Attach the formulary page or excerpt when feasible

Required Prescription Details

Prescriptions should include complete details: drug name (brand and generic), strength, dosage form, quantity, days’ supply, and route of administration. For specialty or infused products, include administration site, infusion schedule, and payer‑required codes.

• Include NDC or exact product description when possible
• Specify route (IV, SC, IM, inhalation, intra‑articular) and administration setting

Provide Documentation When Requirements / Limits Apply

Provide all relevant documentation when Requirements/Limits apply: diagnosis, prior therapies and outcomes, lab results, specialist notes, and dosing rationale. Incomplete submissions increase denial risk and delay therapy.

• Attach prior medication failure documentation for ST requirements
• Include labs or imaging tied to the indication where required

Use Tier and Requirements/Limits When Documenting

When documenting a PA for a specialty product, include the product’s Tier and the Requirements/Limits designation (SP/LA/QL) on the cover sheet. This ensures the reviewer sees the formulary context and applicable plan limits.

• Place Tier and Requirements/Limits prominently in the submission
• For SP products, note any required specialty program or distribution channel

Specialty Product Designation — Provider Actions

Specialty product designation (SP) indicates the need for specialty pharmacy coordination, additional monitoring, and often a higher documentation burden. Start authorization and specialty enrollment early to avoid treatment delays.

• SP examples: many antineoplastics, biologics, and orphan drugs listed on the formulary
• Initiate specialty PA and enrollment prior to first dose

Step / Managed Therapy Indications — Step Therapy Not Specified

Step therapy indications are present in the formulary abbreviations (ST) but explicit step sequences are not listed for every agent in this section. If ST is shown on a drug line, expect to document prior trials of preferred agents; where no explicit sequence is provided, follow plan guidance or contact Member Services.

• ST flag: provider must show trials of required agents before approval
• When step sequences are not specified, contact Member Services for guidance

Managed Access / Potential Step Edits

Managed access and potential step edits may be applied even when explicit step therapy rules are not printed on the line. Assume utilization management may include step edits and verify requirements before prescribing.

• Examples: inhaled antibiotics and specialty formulations often carry SP/LA and may also have step requirements
• Contact Member Services if uncertain about step requirements

Route LA/SP products to infusion center or specialty pharmacy

Certain injectable or specialty-administered products and long-acting injectables marked LA or SP indicate limited access or specialty distribution and may be routed to infusion center or specialty pharmacy.

• Examples: APRETUDE (LA, SP) and TOBI PODHALER (LA, SP) — coordinate with specialty pharmacy or infusion center as required.

Use LA/SP flags to determine site-of-care routing

LA and SP flags indicate specialty or limited-access site/process; follow specialty distribution or infusion routing when these flags are present on the formulary entry.

• Verify site-of-care instructions and coordinate scheduling at an infusion center or specialty pharmacy when needed.

IV biologics with LA/SP often require infusion or specialty distribution

IV biologics listed with LA or SP flags (e.g., ENTYVIO, OMVOH, SELARSDI, TREMFYA) suggest infusion center or specialty distribution requirements — confirm PA and channel prior to administration.

• For IV biologics, obtain PA and coordinate infusion center scheduling or specialty pharmacy fulfillment as indicated.

Route SP/LA, SP products through specialty pharmacy

Products labeled SP or LA, SP indicate specialty pharmacy or limited access handling (examples include tocilizumab, apremilast, upadacitinib); route these to specialty pharmacy and obtain required authorizations.

• Check the Requirements/Limits field and contact specialty pharmacy for enrollment or dispensing instructions.

Administer intra‑articular injectables in office/clinic as indicated

Intra-articular hyaluronic acid products (GEL-ONE, SYNVISC, VISCO-3) are likely administered in office/clinic or infusion setting; verify site-of-care and any PA requirements before scheduling.

• Confirm site-of-care and PA for intra-articular injections prior to administration.

Dispense SP products via specialty pharmacy when required

Specialty-designated products (SP) may require specialty pharmacy dispensing or channel; confirm specialty routing and authorization requirements before prescribing or dispensing.

• If an item is labeled SP, coordinate with the specialty pharmacy and include specialty program documentation in PA requests.